VolitionRx Ltd Announces Prepayment of 2025 Convertible Note

What Happened VolitionRx Ltd (VNRX) announced in an 8-K filed September 14, 2026 that it prepaid in cash the outstanding principal on its 2025 senior secured convertible promissory note held by Lind Global Asset Management XII LLC. The prepayment occurred on September 11, 2026 and totaled approximately $422,000, leaving no remaining balance under the 2025 Note. The original financing was governed by a Securities Purchase Agreement dated May 15, 2025 (as amended and restated January 7, 2026). Separately, a second note issued to Lind in January 2026 (the 2026 Note) and all obligations under it remain in full force and were not affected by this prepayment. The company issued a press release on September 14, 2026 about the prepayment (Exhibit 99.1).

Key Details

• Prepayment date: September 11, 2026; amount: ~$422,000; after payment, no amounts remain outstanding under the 2025 Note.
• 2025 Note original principal: $7,500,000 (dated May 20, 2025); it is a senior secured convertible promissory note convertible into common stock.
• 2026 Note original principal: $2,400,000 (dated January 15, 2026) — remains outstanding and unaffected by the prepayment.
• Transaction counterparty: Lind Global Asset Management XII LLC; underlying Securities Purchase Agreement dated May 15, 2025, amended and restated January 7, 2026.

Why It Matters The prepayment removes the remaining 2025 convertible note liability from VolitionRx’s balance sheet, eliminating future interest/repayment obligations and removing one potential source of stock conversion-related dilution tied to that specific note. However, investors should note that the 2026 Note and its obligations remain outstanding, so the company continues to have debt and potential conversion/dilution risk from that separate instrument. The filing is informational and does not disclose other changes to covenants or terms beyond the reported prepayment.